Advance Hidradenitis Suppurativa Treatment Through Our NYC Study

Are you or someone you know affected by moderate-to-severe Hidradenitis Suppurativa (HS)? This challenging condition, characterized by painful nodules and abscesses, significantly impacts daily life. Join our Phase 3 randomized controlled trial (RCT) in NYC to help advance treatment options specifically for HS with Remibrutinib.

We’re seeking individuals diagnosed with moderate-to-severe HS lasting at least 6 months to join our clinical trial. By participating, you’ll receive specialized care and monitoring while contributing to medical advancements focused on improving HS management.

New York location for dermatology study by Equity Medical
Study Location
New York
Office Address

200 Amsterdam Ave. New York, NY 10023

Office Phone
646-413-6020

Overview

Recruiting start date
  • 9/1/24
Duration
  • 68 Weeks
Population

Adults with moderate-to-severe HS ≥ 6 months.

Study Drug

Remibrutinib

Details: Participants will be randomly assigned to receive either Remibrutinib (66%) or a placebo (23%). After Week 16, all participants will receive remibrutinib 10 mg b.i.d. or remibrutinib 25 mg b.i.d. up to Week 68 in a blinded way.

Design

Phase 3 RCT

Key Exclusion Criteria
  • Presence of more than 20 fistulae/tunnels (both draining and non-draining).
  • Major surgery within 8 weeks prior to screening or planned surgery for the duration of the study.
Compensation
  • To be determined
Studies
Contact us to join a dermatology study clinical trial

Contact Us Today!

Whether it be eczema, dandruff, or psoriasis, being a part of our research is an impactful way to explore treatments and medications. Even if there isn’t a current study that’s a perfect fit for you, take the first step and sign up to learn more and be considered for future studies in New York and Kentucky. Click the button below to get started!